-
2024-511495-32-00
5
2025-04-16
Chronic Phase Chronic Myeloid Leukemia
-
2024-513084-38-00
9
2025-04-15
Recently diagnosed non favorable Acute Myeloid Leukemias
-
2023-505789-27-00
4
2025-04-14
Relapsed or Refractory Non-Hodgkin Lymphoma
-
2024-512496-12-00
5
2025-04-01
Moderate to Severe Plaque Psoriasis
-
2023-504086-23-00
5
2025-03-27
Subjects with PBC with a non-optimal response to UDCA.
-
2024-512729-10-00
4
2025-03-27
Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rea
-
2024-516219-25-00
5
2025-03-25
psoriatic arthritis
-
2024-515256-21-00
5
2025-03-21
Fecal incontinence
-
2024-515566-13-00
5
2025-03-19
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2023-508798-94-00
5
2025-02-11
Heart failure
-
2024-510772-20-00
4
2025-02-06
Rectal cancer locally advanced with microsatellite unstable or mismatc
-
2024-513475-41-00
5
2025-02-03
Multiple Sclerosis
-
2024-512900-20-00
7
2025-01-30
Non-muscle invasive bladder cancer (NMIBC)
-
2023-510322-32-00
5
2025-01-27
patients with incurable, metastatic/recurrent head and neck squamous c
-
2023-510323-30-00
5
2025-01-24
First-line treatment of recurrent or metastatic PD-L1+ head and neck s
-
2023-504554-35-00
5
2025-01-17
incisional hernia
-
2024-516372-14-00
11
2025-01-13
Asymptomatic Patients with frequent PVCs and normal LVEF
-
2023-510507-21-00
10
2025-01-08
Intersitial lung disease related to systemic sclerosis
-
2023-506350-21-00
4
2025-01-06
Localized, resected, FIGO stage I (2018 classification), uterine leiom
-
2024-511596-15-00
4
2024-12-26
Liver Diseases, Alcoholic
-
2023-504022-19-01
5
2024-12-13
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2023-508208-40-00
10
2024-11-21
All adult patients with successful transfemoral trans-aortic valve imp
-
2024-514886-21-00
6
2024-11-06
Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus
(P